MSD's confidence in its anti-TL1A antibody tulisokibart in inflammatory diseases has been made apparent by a decision to start trials of the drug in three more indications. Already in phase 3 testing ...

The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD candidates with blockbuster potential. According to Reuters, MSD – known as Merck & Co in ...

Merck Sharp & Dohme (MSD) has agreed to acquire Cidara Therapeutics in a transaction valued at approximately $9.2 billion, following encouraging results from the company’s phase 2b trial of its lead ...

The Metropolitan Sewer District’s head of government and public affairs is moving over to city government. Louisville Mayor Craig Greenberg said he’s appointed Wesley Sydnor as the new head of Public ...

‘Shocking’ is the first word that lawyers working with survivors of abuse in State care can come up with after they were alerted to a serious privacy breach perpetrated by the Ministry of Social ...

MSD has agreed to acquire Cidara Therapeutics in a $9.2bn deal, adding a new long-lasting infectious disease drug technology to its pipeline. The big pharma company will pay $221.50 per share in cash ...

Enlicitide significantly reduces LDL-C in patients with high cardiovascular risk MSD has announced positive results from its phase 3 CORALreef Lipids trial, showing that enlicitide decanoate, an ...

The regimen’s safety profile matched earlier data, and further analysis is continuing. Credit: Minerva Studio / Shutterstock.com. Merck & Co (MSD) and Eisai are set to discontinue their Phase III ...

MSD’s Winrevair received approval based on data from the Zenith trial. Credit: JHVEPhoto/Shutterstock.com. MSD has received US Food and Drug Administration (FDA) approval for an updated indication of ...

The trial has shown curability of the combination over a five-year period. Image credit: Nemes Laszlo / Shutterstock.com MSD and Eisai’s combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib ...

MSD HYDERABAD GLOBAL CAPABILITIES CENTER INDIA PRIVATE LIMITED is a Private Limited Company, governed by the Companies Act as a company limited by shares. Classified as a Non-government company, it is ...